November 29, 2021
COVID-19 vaccine is a vaccine that aims to provide acquired immunity against COVID-19 disease.
Before the 2019–2020 coronavirus epidemic, work on developing vaccines against coronavirus diseases revealed information about us and the function of coronaviruses, and this accelerated the development of various technology platforms in early 2020 to develop a vaccine that would protect against COVID-19. Thousands of scientists have tried to produce a vaccine against SARS-CoV-2. The World Health Organization has published on its website the names of 41 potential compounds that may be the vaccine under trial for vaccination. The news from the trials was that a vaccine might be available after 12 or 18 months. In the December 2020 transcript, there were 57 candidate grafts in a clinical research phase. 40 of them were in the phases of the first and second phase experiments. 17 of them were in the second and third phases of experiments.
Herd immunity against covid-19 is still unknown.
In November 2020, BioWaynetech & Pfizer, Moderna, Oxford University (in collaboration with AstraZeneca), and Jamalia Institute announced positive results from interim analyzes from phase 3 trials. As of December 18, 12 countries have allowed Pfizer-Bioinetech to be a vaccinate for COVID-19 to be used in emergencies. Also, Bahrain allowed it to be used in emergency situations, the manufacture of Sinopharma, followed by the Emirates. As of December 16, in the United Kingdom, 138,000 people have received a Pfizer-BiWaynetech COVID-19 vaccine in the first week of the vaccination programme.
COVID-19 vaccines - Pictures, audio and video recordings on Wikimedia Commons (English)